AstraZeneca PLC (LON:AZN - Get Free Report) insider Tony Mok bought 1,500 shares of the business's stock in a transaction on Tuesday, November 19th. The shares were acquired at an average cost of £126.80 ($160.45) per share, for a total transaction of £190,200 ($240,668.10).
AstraZeneca Price Performance
Shares of LON:AZN opened at GBX 9,969 ($126.14) on Thursday. The company has a debt-to-equity ratio of 84.97, a quick ratio of 0.59 and a current ratio of 0.89. The company has a market capitalization of £154.52 billion, a PE ratio of 3,164.76, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The stock has a fifty day moving average of £114.45 and a 200-day moving average of £120.91. AstraZeneca PLC has a one year low of GBX 9,461 ($119.71) and a one year high of £133.88 ($169.40).
Analyst Ratings Changes
A number of equities analysts recently issued reports on the stock. Berenberg Bank reiterated a "buy" rating and issued a £150 ($189.80) target price on shares of AstraZeneca in a research report on Monday, September 2nd. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a £110 ($139.19) target price on shares of AstraZeneca in a research report on Tuesday, September 3rd. Shore Capital reiterated a "buy" rating on shares of AstraZeneca in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. restated an "overweight" rating and issued a £140 ($177.15) price objective on shares of AstraZeneca in a report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of £104.12 ($131.75).
[625,000% Gain] – Are You Ready for the Next Altcoin Boom?
From Crypto Swap Profits | Ad
All of our key indicators are flashing the same signal: an altcoin season is fast approaching.
And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
Register for the FREE Workshop Now & get $10 in Bitcoin
View Our Latest Report on AZN
AstraZeneca Company Profile
(
Get Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
